Targets › POLG
8 programs from 7 companies in 27 trials: 11 Phase 3, 10 Phase 2, 5 Phase 4, 1 Phase 1; Infectious disease, Oncology, Neurology; next expected readout Dec 2026.
Catalytic subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Replicates both heavy and light strands of the circular mtDNA genome using a single-stranded DNA template, RNA primers and the four deoxyribonucleoside triphosphates as substrates. (UniProt, P54098)
Open in Phaseline: the race on POLG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bangladesh Medical University | Entecavir DNA polymerase/reverse transcriptase inhibitor | POLG | Phase 4 | Hepatitis B | Jan 2027 |
| University Health Network, Toronto | Entecavir DNA polymerase/reverse transcriptase inhibitor | POLG | Phase 4 | Hepatitis B Virus (HBV) | Aug 2027 |
| ANRS, Emerging Infectious Diseases | Tenofovir Disoproxil Fumarate (TDF) Nucleotide reverse transcriptase inhibitor (NtRTI) - inhibits HBV reverse transcriptase | POLG | Phase 4 | Hepatitis B Virus - Chronic Active | Aug 2027 |
| Sun Yat-sen University | Entecavir DNA polymerase/reverse transcriptase inhibitor | POLG, POLB | Phase 3 | Gastrointestinal Cancers; Resolved Hepatitis B | Dec 2026 |
| Merck & Co. (MSD) | Islatravir Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLG, RT | Phase 3 | HIV-1 Infection; HIV Infection; Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Aug 2027 |
| Merck & Co. (MSD) | Doravirine Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator | RT, POLA2, POLG | Phase 3 | HIV-1 Infection; Human Immunodeficiency Virus (HIV) Infection; HIV-1-infection; HIV … | Jul 2028 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Tenofovir alafenamide (TAF) Nucleotide reverse transcriptase inhibitor (NtRTI), prodrug of tenofovir | POLG | Phase 2 | Healthy Volunteer | Jan 2028 |
| National University Hospital, Singapore | Descovy (TAF/FTC) Combination reverse transcriptase inhibitor - nucleotide RTi (TAF) and nucleoside RTi (FTC | POLG | Phase 1 | Mild Cognitive Impairment (MCI) | – |
HIV-1 Infection (6) HIV-1-infection (4) Human Immunodeficiency Virus Type 1 (HIV-1) Infection (2) Human Immunodeficiency Virus (HIV) Infection (2) Healthy Volunteer (2) Gastrointestinal Cancers (1) Resolved Hepatitis B (1) HIV Infection (1) Hepatitis B (1) Hepatitis B Virus (HBV) (1) HIV (1) HIV - Human Immunodeficiency Virus (1)
small molecule (7), mixed (1)
Merck & Co. (MSD) (2) Sun Yat-sen University (1) Bangladesh Medical University (1) University Health Network, Toronto (1) National University Hospital, Singapore (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) ANRS, Emerging Infectious Diseases (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.